Evaluation Using FAPI-PET Targeting Cancer-associated Fibroblasts

illustrative image

The company Tadashi Watabe is commencing recruitment for the clinical trial of the Evaluation Using FAPI-PET Targeting Cancer-associated Fibroblasts.

The trial officially began on the May 9, 2022 and is planned to complete on March 31, 2024.

PET / CT examination using [18F] FAPI-74 is performed on patients diagnosed with malignant tumor, and the pathological condition is determined by comparing with FDG-PET/CT examination of conventional diagnostic imaging.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05442151 or https://clinicaltrials.gov/ct2/show/NCT05442151.

Clinical Research News

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults
A new study of Dexpramipexole in adolescents and adults with severe Eosinophilic Asthma

Upcoming Clinical Trials

Evaluation Using FAPI-PET Targeting Cancer-associated Fibroblasts

All jobs

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe